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Abstract
With the recent advances in the immunological surveillance system, an understanding of the
role of host immunity has become essential to the management of carcinogenesis, tumor prolif-
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treatment of cancer, support of the anti-tumor immune system of the host should also be consid-
ered. Long term remission has been reported in leukemia by treating with BCG after chemotherapy
whereas surgical treatment is usually more effective in preventing cancer recurrence in digestive
organ cancer. The first step is extirpating the tumor as thoroughly as possible and the second step
is chemo-immunotherapy. Cancer immunity, however weak, constitutes the basis for other treat-
ments in selectively attacking cancer cells remaining after surgery, chemotherapy or irradiation.
Immunotherapy should thus not replace chemotherapy or radiotherapy, but these methods should
be employed in combination to attain more favorable results.
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Abstract. With the recent advances in the immunological surveil-
lance system, an understanding of the role of host immunity has be-
come essential to the management of carcinogenesis, tumor prolifera-
tion, recurrence and metastasis. Although it is important to continue
chemical and surgical treatment of cancer, support of the anti-tumor
immune system of the host should also be considered. Long term re-
mission has been reported in leukemia by treating with BCG after
chemotherapy whereas surgical treatment is usually more effective in
preventing cancer recurrence in digestive organ cancer. The first step
is extirpating the tumor as thoroughly as possible and the second step
is chemo-immunotherapy. Cancer immunity, however weak, consti-
tutes the basis for other treatments in selectively attacking cancer
cells remaining after surgery, chemotherapy or irradiation. Immuno-
therapy should thus not replace chemotherapy or radiotherapy, but
these methods should be employed in combination to attain more
favorable results.
Tumor proliferation should be considered in terms of its inter-relationship to
host resistance. So far, the role of host resistance has been vague with treatment
being directed only at the tumor so that postoperative recurrences seemed to be
entirely due to inability of the operating surgeon to extirpate all tumor tissue. We
have, however, encountered cases of progressive cancer where metastasis ap-
peared to have been triggered by the operation, and seemed to hasten death,
whereas other cases of partial tumor extirpation showed long remission or sur-
vival. Moreover, occasional cases of spontaneous remission are reported. These
varied responses indicate that host resistance is involved in tumor proliferation.
With the recent remarkable advances in immunology, it has become clear
that host resistance consists of an immunological surveillance system which is
centered on T -lymphocytes. Thus immunological support of the host appeared
as a rational mode of cancer treatment. One problem is assessing to what extent
the host can reject cancer. Numerous other factors include the immune capacity
of the host which resides in the Ia gene and tumor antigenecity. Klein et at. (1)
showed that up to 106 viable autochthonous methylcholanthrene-induced tumor
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cells were rejected, but at above 10 7 cells, tumor death resulted in mice regard-
less of the degree of immunization by X-irradiated autochthonous tumor cells.
Mathe et at. (2) reported that, in their experiments with F 1 mice and transplanta-
tion of L-1210 leukemic cells resistant to all treatment, the number of tumor
cells rejected in untreated F 1 mice was low, but that up to 10 5 cells were rejected
when the mice had been previously well immunized with either BCG or irradiated
L-121O cells. The results indicate enhanced antitumor activity as a consequence
of immunotherapy.
In human terms, this is equivalent to 6 X 106 cells or 0.6g of tumor mass.
Mathe et at. (3) after inducing remission in 30 childhood cases of acute lympho-
cytic leukemia by intensive chemotherapy divided them into four groups: 10
untreated controls (Group I), 8 cases given BCG (Group II), 5 cases given sub-
cutaneous injection of leukemic cells (Group III) and 7cases given injection of
leukemic cells mixed with BCG (Group IV). These investigators administered
150 mg of viable Pasteur BCG by the scratch method every 4 days for the first
month, and thereafter once weekly. In Group I and Group III, recurrence oc-
curred· in all cases within 130 days, but in Groups II and IV a long period of
remission ranging from 4.5 to 7 years was attained.
Immunotherapy conducted after the tumor decreased in size was definitely a
more successful method of treatment. Chemotherapy is required for progressive
solid tumors where remnants are apt to occur and for leukemia of the fluid form.
One disadvantage of present chemotherapy methods, however, is the lack of selec-
tive action, and, at present, there is a limit to the percentage of cancer cells
killed by chemotherapy which is unrelated to the original number of cancer cells
(4). That is, the dose of anticancer agent necessary to decrease 10 12 tumor cells
to 109 cells (1 kg~lg) should theoretically be the same as that required to de-
9 6crease 10 cells to 10 cells (Ig~ Img). Estimates have shown that even when
an anticancer agent is administered at the maximum tolerant dose, about 109
cancer cells survive. Moreover, due to lack of selectivity, the bone marrow and
lympho-reticuloendothe1ial systems are disturbed and this results in depression of
the immune system, so that subsequent immunotherapy is less successful. With
solid tumots, surgical intervention may cause a slight disturbance in the immune
system but much less so than an anticancer agent. The tumor mass is thus re-
duced (reduction surgery), and with subsequent immunochemotherapy, a higher
success rate than that reported for leukemia by Mathe may be anticipated. We
will discuss our findings on both how cancer patient immunity is affected by
surgery and the role of postoperative immunotherapy.
Indices of Immune Capacity in Cancer Patients
The ability to produce humoral antibody is generally maintained to the
terminal stage in patients with solid tumors. The problem is the cell-mediated
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immunity. In examining cell-mediated immunity of cancer patients, two factors
require examination: (a) specific cell-mediated immunity that, recognizing
tumor specific transplantation antigen (TSTA) and tumor specific antigen (TSA) ,
reacts against them, and (b) non-specific cell-mediated immunity that represents
the general biological activity and the numbers of lymphocytes. Such examina-
tions should not aggravate the condition of the patient and should be reproduci-
ble. Skin tests with recall antigens such as pure protein derivative (PPD) and
dinitrochlorobenzene (DNOB) are frequently used in vivo as an index of non-specif-
ic cell-mediated immunity. In vitro tests generally used include: blastformation
of T -lymphocytes against phytohemagglutinin (PHA) and concanavalin A, and
the ratio of peripheral T -cells and B-cells. The parameters of specific cell-
mediated immunity are mainly in vitro tests. In vitro tests include: lymphocyto-
toxicity tests where lymphocytes are added to autochthonous cancer cells or to
established homologous cancer cells with cross-antigens; colony inhibition tests
OI-test) ; and estimation of lymphokines liberated from immunized lymphocytes
in response to tumor antigens, especially assay of macrophage migration inhibi-
tion factor (MIF) and leukocyte migration inhibition factor (LIF), and estimation
of the blastformation rate of peripheral blood lymphocytes to autochthonous
tumor antigens (mixed lymphocyte-tumor reaction, MLTR). When these tests
are positive, the presence of specific cell-mediated immunity, TSTA and/or TSA
is indicated.
If target cancer cells and their antigens are treated with the cancer patient
serum prior to the addition of lymphocytes, blocking factors may be measured in
serum. It is thus possible to demonstrate specific cell-mediated immunity and
the presence of cross-antigens in human cancer of the same histological type (such
histological types include melanoma, leukemia, neuroblastoma, colon cancer, and
gastric cancer) .
Preoperative Cell-mediated Immunity in Cancer Patients
In both animal and human ccancer (5-7) specific cell-mediated immunity
develops first in the regional lymph nodes and such immunity grows stronger as
the tumor progresses, and as the tumor increases beyond a certain level, this
specific immunity weakens in the regional lymph nodes and appears in more
distant lymphatic tissues and peripheral blood lymphocytes (5-7). Specific cell-
mediated immunity in even peripheral blood lymphocytes disappears by the
terminal stage of cancer. In lymph node cells of progressive gastric cancer, the
cytotoxicity is stronger at the distal mesentery lymph nodes than at the regional
lymph nodes. O'Toole et ale (8) have classified urinary bladder cancer into stage
T 1 to T 4: in mucosa (T1), infiltration stopping at the muscle layer surface (T 2),
infiltration into deep muscle layer but the tumor is mobile (T3) and infiltration
out of the bladder wall and immobile (T4)' They reported that positive lympho-
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cytotoxicity was found in 88% of T 1 - T 2 cases, while it was 41 % in T 3 -T 4 cases.
Positive MIF in peripheral blood lymphocytes was found in gastric cancer pa-
tients in 6 of 14 Stage I cases (42.9%), in 13 of 23 Stage II cases (56.5%), in 28
of 55 Stage III cases (50.9%) and in 14 of 44 terminal Stage IV cases (31.5%).
Even with colon cancer, the tendency was similar. McCoy et al. (9) found that
LIF was positive in 11 of 15 Stage I cases (75 %) of melanoma with localized
tumor, in 16 of 27 Stage II cases (50%) with regional lymph-node metastases and
in 21 of 37 Stage III cases (57%) with distal metastases.
Non-specific cell-mediated immunity was inversely proportional to the ad-
vance of cancer. The positive rate of both the tuberculin test and DNCB reaction
decreased along with the progress of gastric cancer and colon C..lncer. Sheep red
blood cell rosette-forming cells (T-cells) also tended to decrease in progressive
gastric cancer. A clear-cut mutual relationship was especially present between
PHA-blastformation rate and cancer progress, and a successful operation for
cancer appeared possible if the preoperative blastformation rate was over 40% in
gastric cancer and colon cancer. If the blastformation rate was 30-40%, a non-
curative operation was indicated, and if the rate was under 30 % and DNCB test
negative, a palliative operation was likely. Our own data indicate that a PHA-
blastformation rate of 40 % is the critical point.
Reasons for Decreased Cell-Mediated Immunity in Progressive Cancer
Until the tumor reaches a certain size, lymphocytes have positive lympho-
cytotoxicity. The mechanisms of cancer cell rejection is complex. Cancer cells
are attacked by many different cells, such as effector T -cells that adhere directly
to cancer cells and destroy them, B-cells and macrophages with Fe-receptors on
their cell surface, and small lymphocyte-like K cells on whose cell surface there
is no demonstrable immunoglobulin. The last three types of cells are thought to
have humoral antibody controlled by the T -lymphocyte or with lymphokines
produced by T -lymphocytes, and attack cancer, and the T -lymphocytes probably
play the main role in the rejection of cancer cells (10). As cancer advances, an
excessive amount of tumor antigens is liberated surpassing the disposal capacity
of the host. Such antigen conjugates with the receptor of the T -lymphocyte and
neutralizes it, and by further combining with the antibody produced by B-cells,
forms an antigen-antibody complex (a blocking factor). The blocking factor
combines with the immune T-Iymphocytes and cancer cells, and thus inhibits the
cytotoxic activity of the immune T -lymphocytes. There is also an increase of
non-specific immunosuppressive factors, such as a2-globulin, carcino-embryonic
antigen and toxohormone produced by the tumor itself in progressive cancer.
The decrease of cell-mediated immunity in progressive cancer may arise from the
large tumor itself, as well as from the spleen with numerous B-cells that produce
the antibody and with suppressor cells (Fig. I).
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Fig. 1. The progress of cancer and changes in cell-mediated immunity. In a relatively
early stage of cancer, tumor antigen reaches the regional lymph nodes in adequate doses and
generates immune T-cells that attack the cancer focus. With the growth of tumor, an over-
dose of tumor antigen makes the immune T-cells tolerant and blocking factor, a complex
of antibody and tumor antigen, specifically inhibits the activity of immune T-cells. Massive
toxic substances, such as toxohormone are produced by the cancer focus that inhibit the
T-cells.
Postoperative Cell-Mediated Immunity in Cancer Patients
Postoperative cell-mediated immunity may be suppressed by anesthesia,
surgical intervention and tumor extirpation. It is already known that phago-
cytosis of the reticuloendothelial system is markedly decreased after hemicolec-
tomy in dogs (11). Slade et al. (12) have observed changes of immunity in vitro
and in vivo before, during and after nephrectomy in 12 renal donors. The average
time for anesthesia was 4 hr and the average duration of operation was 3
hr. Anesthesia was induced with pentothal in all cases, and for maintenance,
fentanyl was given to 10 cases, and halothane or ethrane was administered to
another two cases. As in vitro criteria, peripheral blood lymphocyte counts, T -and
B-cell counts, PHA-blastformation rate and one-way MLC (mixed lymphocyte
culture) tests were used. As soon as anesthesia took effect, immunity began to
weaken and reached a minimum level at 24-48 hr after the operation, and by
the fifth postoperative day the immunity returned to approximately the preopera-
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tive level. For in vivo criteria Slade et at. used skin tests with recall antigens. The
skin reactions started to decrease gradually at induction of anesthesia and tended
to reach a minimal level by the fifth post-oparative day. It required 10-14 days
for complete recovery of the skin reaction by SK-SD and it took over 2-3 weeks
with mumps and candida. There was no change in serum globulin level. It is
worth noting that a time difference was present between immunity changes in
vivo and in vitro.
Eilber and Morton (13) extirpated tumors as thoroughly as possible in sar-
coma and melanoma cases and started immunotherapy with BCG at 3-6 post-
operative weeks while continuing the DNCB test every two weeks. They im-
munized sarcoma cases with a mixture of BCG end established sarcoma cells (10 8
cells). The prognosis was good in melanoma cases with positive DNCB tests
preoperatively. Recurrence was seen in only 3 of 21 cases (14 %) that turned
positive after the operation out of 51 cases negative before the operation, recur-
rence was seen in 22 of 30 cases (74%) that were negative throughout, and
recurrence was present in all seven cases that turned negative after the operation.
Similar results were obtained even with sarcoma cases. Hersh et at. (14) adminis-
tered chemotherapy to adults with acute leukemia where they had repeated skin
tests with dermatophytin 0, candida and mumps. The skin reactions decreased
once after chemotherapy but recovered within 6 months and were maintained
positively in cases having remission periods over one year. However, such reac-
tions decreased one month prior to recurrence in cases having recurrence within
one year.
In following up the PHA-blastformation rate of peripheral blood lympho-
cytes after the operation, most cases showed a low value up to the second post-
operative week, but the rate became stable thereafter. Comparisons of the blast-
formation rate before and 4 weeks after the operation indicated that the post-
operative rate tended to rise slightly in 12 cases of benign diseases and in 42 cases
receiving curative cancer operation, while the rate was decreased further from
34.2% to 28.1 % in cases undergoing palliative operations. Ten of 15 cases of
gastric cancer with preoperative blastformation rates of less than 40% showed
rates above 40 % at 4 postoperative weeks after the curative operation, and the
rates were over 40% in all cases with favorable clinical courses over a period of
one to two years. With recurrent cases, the blastformation rate on the way to
recovery fell acutely 2-3 months before clinical confirmation of recurrence (Fig.
2). In 70 cases with favorable postoperative clinical courses and 99 cases with
recurrences after discharge, the blastformation rate was 51 % and 29% respec-
tively. As long as the tumor was completely extirpated, the T -lymphocyte
function recovered gradually even in advanced cancer.
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Fig. 2. Changes in PHA-blastformation rate before and after the postoperative
recurrence of gastric cancer. The arrow indicates the time of the recurrence.
PHA-Blastformation rate decreased 2 months before clinical confirmation of recur-
rence.
Tumor extirpation and blocking factors. Hellstrom et al. (15) found in isotrans-
plantation of methylcholanthrene-induced (MC) sarcoma of mice that the block-
ing factor decreased at four days after tumor removal. Heppner (16) transplanted
spontaneous mammary cancer maintained by serial passage in syngeneic mice
and divided these mice into three groups: complete tumor extirpation 3-10
weeks after transplantation when the tumor became palpable, sham-operated and
untreated. These investigators estimated the tumor-colony formation-inhibitory
activity (CI activity) of lymph node cells and the blocking factor in their sera at
10-15 postoperative days when the tumors of the latter two groups grew to 10-
20 mm in diameter. CI activity was positive in 12 of 13 cases of the extirpated
group, in 12/15 cases of the sham-operated group and in 7/17 cases of the un-
treated group, giving the impression of a rise in cell-mediated immunity in the
sham-operated group. The blocking factor was positive: in 5/6, 2/4 and 2/5
cases, respectively, in postoperative days 1-5; in 4/13, 5/9 and 6/10 cases, re-
spectively, in postoperative days 10-15; and the blocking factor decreased signi-
ficantly along with the lapse of time as 5/6 to 4/1'3 cases in the extirpated group.
Positive lymphocytotoxicity was present in both the isotransplanted polyoma
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tumor group and the tumor-extirpated group, while the antitumor activity was
so strong as to reject the replanted tumor in the tumor-extirpated animals not
demonstrating blocking factor, compared with tumor-bearing animals with
blocking factor (17). A deblocking factor that neutralized the blocking factor
was produced in serum within one week after polyoma tumor extirpation. There
is no report of a blocking factor with a lapse of time in human cancer, but block-
ing factor was found in extensive, progressive cancer patients. The blocking
factor was obliterated in serum of patients undergoing curative operations (18).
In extensive melanoma-metastasis cases positive blocking factor was found in
87% of cases, while it was negative in all cases of localized melanoma and during
remission (19). Moreover, it is said that complement dependent antibody with
antitumor activity appears in completely extirpated localized melanoma (20).
Maluish and Halliday (21) stated that if melanoma is sufficiently removed, block-
ing factor is demonstrated in the second postoperative week but disappears in the
seventh week.
Tumor extirpation and lymphocytotoxicity. In 1966 Mikulska et at. (22) found no
inhibition of tumor growth in spleen cells of mice bearing benzopyrene-induced
sarcoma, but anti-tumor activity appeared in spleen cells three weeks after tumor
extirpation, with an in vivo neutralization test of implanting a mixture of spleen
cells and sarcoma cells to other normal syngeneic mice. Barski and Youn (23)
found positive CI-activity in peritoneal cells (40% lymphocytes and 57% macro-
phages) of mouse isotransplanted subcutaneously with Rauscher virus-induced
sarcoma on post-transplantation day 9 when the tumor was 2-5 mm in diameter,
but CI-activity turned negative on day 40 when the tumor reached 20 mm in
diameter. It became positive 12 days after extirpation on transplantation day 17
when the tumor was 10-15 mm in diameter, and it was still positive 56 days
later. Hellstrom et at. (24) reported that peripheral blood lymphocytes main-
tained antitumor activity for several years and to a maximum of 29 years after
remission of melanoma and colon cancer. On the other hand, O'Toole et at. (25)
found that the cytotoxicity of peripheral blood lymphocytes disappeared by 4-8
postoperative weeks in cases where the urinary bladder cancer was completely
extirpated, but cases with residual tumor tissues showed strong cytotoxic activity
even at the fifth postoperative week. Irradiation at 4,OOOR at 4-6 weeks before
surgery reinforced cell-mediated immunity, and the cytotoxic activity was main-
tained for 3-6 postoperative months. This is probably due to liberation of anti-
gen from the tumor which became necrotic by irradiation.
The foregoing are reports concerned with cases where the blocking factor
was mainly decreased by tumor extirpation and where the lymphocytotoxicity
rose. In vivo the antitumor activity was reinforced. It is not unusual, however,
to observe metastasis and aggravation of tumor following operation because cell-
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mediated immunity is decreased merely by anesthesia or surgical intervention
alone. According to Greene and Harvey (26), lymphoma cells were demonstrated
in circulating blood of most hamsters transplanted s.c. with these tumor cells 7
days earlier, but these hClmsters survived for one month without metastasis.
However, when the tumor was extirpated on the 13th day after transplantation,
metastasis occurred in 62.7% of hamsters. Stjernsward (27) also observed the
decline in concomitant immunity and the ready growth of the retransplanted
tumor after radical operation in mice bearing MC-induced sarcoma. Gershon
and Carter (28, 29) also found in homotransplantation of lymphoma to hamsters
that when the tumor was extirpated one week after transplantation, metastasis
formation was accelerated, but when tumor was replanted, the immunity re-
covered. The fact that the presence of the main tumor inhibited metastasis was
also shown with MC-sarcoma in mouse (30).
Tumor extirpation, macrophage migration inhibition factor (MIF) and leukocyte
migration inhibition factor (LIF) .
Many reports indicate that MIF and LIF may be used as criteria for specific
cell-mediated immunity and that they decrease after tumor extirpation. MIF
and LIF differ in molecular weight and must have different biological activity
but clinically they might be taken as the same thing without much inconvenience.
McCoy et al. (9) stated that LIF in melanoma decreased after operation but
returned practically to the normal level within 11-30 days, and even one year
later was positive in 16 of 27 cases (59%). Cochran et al. (31) similarly reported
that LIF declined within 4-5 days after the operation in practically all cases of
melanoma and mammary cancer but recovered to the preoperative level 6-22
days later. Andersen et al. (32) obtained contrary results in that LIF disappeared
one month after the operation in mammary cancer cases with a favorable course
without recurrence. Lurie et al. (33) observed that LIF turned negative in all
seven cases with localized colon cancers which were completely extirpated at the
second postoperative month. In our gastric cancer cases, the positive MIF re-
sponse of peripheral blood lymphocytes before the operation disappeared at one
month after the operation in 7 of 9 cases of Stages I and II where the main lesion
including the metastatic foci were believed to have been removed radically. On
the other hand, MIF which was negative prior to the operation became highly
positive after the operation in 13 of 17 cases of Stage IV where the tumor had
been thoroughly extirpated (Table 1).
To clarify the relationship between the tumor mass and MIF, we implanted
s.c. MC-sarcoma to syngeneic mice, extirpated tumor weekly as radically as
possible and periodically assayed the MIF changes in the regional axillary lymph
nodes. Where the tumor corresponded to Stage I and II of gastric cancer, the
MIF decreased rapidly in the group undergoing tumor extirpation one week after
9
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TABLE 1. CHANGES IN MIF VALUES BEFORE AND AFTER OPERATION
IN GASTRIC CANCER PATIENTS
Stage
I and II
III
IV
Before
operation
+
+
+
One month after
operation
+
+
+
Patient ratio
7/9
4/12
7/11
7/10
1/6
13/17
%
77.8
33.3
63.6
70.0
16. 7
76.5
-------------
In Stage I and II 77.8% of patients with positive MIF before the operation turned nega-
tive after the operation, and 33.3% of patients with negative MIF turned positive after the
operation. In Stage IV patients with tumor extirpated thoroughly, 16.7% of patients turned
from positive to negative MIF and 76.5% of patients turned from negative to positive
MIF. The MIF response between Stage I and II versus Stage [V was statistically significant.
tumor transplantation. When the tumor was equivalent to Stage IV, the MIF
activity quickly became positive with tumor extirpation three weeks after trans-
plantation, but disappeared rapidly on recurrence (Fig. 3\. Recurrence occurred
in 14 % of mice in the former group and in 90 % of the latter group.
2 3 4
Weeks after transplantati on
Fig. 3. Tumor extirpation after transplantation of Me tumor and MIF of
regiona11ymph nodes. 8- - -e, Control; e--_, extirpation one week later;
0- - -0, extirpation two weeks later; 0--0, extirpation three weeks later;
MI, macrophage migration inhibition. In the control group the MIF activity
reached maximum at 10 days and decreased as the tumor proliferated. However,
at tumor extirpation one week after transplantation, MIF turnd negative rapidly.
At tumor extirpation 3 weeks later, MIF turned positive rapidly, and thereafter
it rapidly became negative with tumor recurrence.
10
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When mitomycin C treated Ehrlich cancer cells were transplanted to six
groups of mice in six inoculation sizes from 10 3 to 10 8 tumor cells, and the MIF
of the regional axillary lymph nodes estimated periodically after transplantation,
the greatest MIF activity was observed in the group receiving 10 5 tumor cells
(Fig. 4).
100
,-..,
~
.......
.c 500:;
0';:;
()
C1l
~
10 4 10 5 106 10 7
implClntcd cell number
Fig. 4. Number of mitomycin-treated Ehrlich cancer cells subcutaneously im-
planted and the MIF at the regional lymph nodes at day 10 after implantation.
The figure shows the relationship between the tumor mass and MIF. The greatest
MIF activity was observed in the group receiving 105 Ehrlich cancer cells.
Akiyama (34) also stated that cases including gastric cancer whose MIF
turned negative in 1-1.5 postoperative munth were at relatively early cancer
stages. These findings indicate that a certain quantity of tumor tissue or tumor
antigen is necessary for positive MIF activity. Such findings lead us to a working
hypothesis that postoperative immunotherapy using the resected tumor is neces-
sary in patients undergoing complete tumor removal.
Postoperative Immunotherapy
Summarizing the immunity changes in cancer patients before and after the
operation, it may be said that non-specific cell-mediated immunity gradually
recovers as long as the tumor is completely extirpated, but there is a danger of
rapid obliteration of specific cell-mediated immunity. Postoperative specific cell-
mediated immunity should playa role in the rejection of remnant cancer selec-
tively and in prevention of recurrence. However, such rejection power is not as
strong as earlier mentioned. Consequently, it is necessary at an early stage of
cancer to provide immunotherapy using resected autochthonous tumor tissue, and
11
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in progressive cancer to diminish the residual tumor tissues. Anticancer agents
should be administered carefully preserving the immune system with some
immuno-potentiators to increase cell-mediated immunity. There are nonspecific
and specific methods in immunotherapy, and the most effective method available
today is immunotherapy centering around BCG. In the NIH protocol of im-
munotherapy, the viable BCG, bacterial component, anaerobic corynebacterium
and levamisole are used. Cancer types and immunization methods are indeed
diverse, but immunotherapy against gastric cancer is rare. Recently, Falk et at.
(35) sprayed 2 mg BCG in the abdominal cavity before closure of the abdominal
wall, and 120mg BCG was given orally every week combined with 5-FU and
endoxan for 8 weeks to 37 gastric cancer or colo-rectal cancer cases that received
simple laparotomy. They found that such treatment was especially effective in
colon cancer in which the average survival of 19 cases was 13.2 months, and
within this group, survival of liver metastasis patients was 12.8 months, being
about 2.5 times greater compared with 146 days of the control group without
immunotherapy.
We have conducted immunotherapy in our patients with BCG or BCG-CWS
made by Yamamura and Azuma of Osaka University. After i. d. isotransplanta-
tion of MH 131 hepatoma cells to C3H mice, the animals were divided into five
groups: (a) the untreated control group, (b) the group with tumor extirpation
two weeks after transplantation, (c) the group with tumor extirpation and i.d.
injection of 4 mg BCG, (d) the group with tumor extirpation and i.d. injection of
mitomycin treated MH 134 cells and (e) the group with tumor extirpation and
i.d. injection of a mixture of mitomycin treated MH 134 cells plus BCG. In the
control group (a) MIF in the regional lymph nodes reached a maximum on the
sixth day of transplantation and decreased as the tumor grew larger and disap-
peared within two weeks. In groups (b) and (d) MIF underwent about the same
changes as in group (a); in group (c) MIF showed slight reinforcement; and in
group (e) receiving combination treatment, MIF continued to grow stronger for
about 20 days. The 50% survival days of each group was: 24,49,47,47 and
93 days, respectively. Group (e) immunized with BCG plus tumor cells simult-
aneously with tumor extirpation showed a significant prolongation in survival
time and sustained reinforcement of MIF (36).
In the period between November 1973 to November 1975, immunotherapy
was conducted on our gastric and colon cancer patients where at least the main
tumors could be extirpated by the following protocol. Free tumor cells were
isolated from 0.5g of homogenized autochthonous tumor tissue and were treated
with 12.5mg/ml of mitomycin C for 30 minutes. Such cells plus O.l-lmg BCG
were injected i.d. to the exterior side of upper arm of the patient on day 1-2 after
the operation. The remaining tumor cells were kept in a liquid nitrogen bomb,
12
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and the same treatment was performed repeatedly at 2, 4, and 8 postoperative
weeks according to the harvested tumor cell number. Mitomycin C, 5-FU and
futraful were given as anticancer agents, and in some cases PS-K or ATSO was
given in conjunction. Examination as shown in Table 2 was conducted periodi-
cally. No side effects were noted, except for a shallow ulcer persisting for 2-3
weeks on the injection site. Table 3 shows ten cases of gastric cancer and three
TABLE 2. CLINICAL AND IMMUNOLOGICAL EXAMINATIONS CONDUCTED
ON PATIENTS OF THE STUDY
Clinical examinations
Hematological examinations
Classification of white blood
cells
Thrombocytes
Urinary examination
Liver function
Serum protein
Chest X-ray
Scintigram
Lymphangiography
Immunological examinations
Skin tests
PPD reaction
DNCB reaction
Lymphocyte blastformation rate
T and B-cell ratio
Macrophage migration inhibitory
test
Lymphocytotoxici ty test
Immunoglobulins
Clinical and immunological examinations were performed periodically during the
follow-up period in all cases receiving immunotherapy.
TABLE 3. PATIENTS TREATED BY BCG IMMUNOTHERAPY
No. Age Sex Stage PP . SurvivalBCG D reactlOn (months) Presentstatus
Alive
Dead
Dead
Dead
Dead
Alive
Dead
Alive
Alive
dead of other disease
Alive
Alive
Dead
(liver metastasis)
(cancerous peri tonitis)
(cancerous peritonitis)
(cancerous peritonitis)
(colon metastasis, ileus)
(icterus)
(liver metastasis)
(renal failure)
-----------
1 75 MIII +.-7+ 37
2 64 MIII + .-7 + 13
3 69 MIII + .-7 28
4 69 MIII - -c> ± 20
5 46 F IV, N4PI +PSK ±.-7 + 10
6 63 F IV, PI +.-7 ± 39
7 70 M IV, HI +PSK +.-7+ 9
8 51 M IV, P3S3 -.-7 10
9 60 F IV, P3 +PSK ± -> ± --;> + 16
10 67 F IV, Pz -I-pSK + 7
11 58 M D-C, H3 -r .-7 + .-7* 25
12 67 M D-B, + .-7 -+ 4
13 70 M D-C, H3 -- .-7 -+ 21
Ten patients were operated on for gastric cancer and 3 patients for colon cancer. All
patients received BCG plus autochthonous tumor cell injections at least 3 times. The
stage of cancer was III or IV in gastric cancer and Dukes C or B (D-C or D-B) in colon
cancer. In some cases PSK, a kind of polysaccharide extracted from Coriolus Vesicolor
Quel, was used.
PPD skin tests were measured before the operation and after the termination of im-
munotherapy.
13
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cases of colon cancer treated by BCG plus autochthonous tumor cell injection at
least 3 times. Gastric cancer in Stage IV represents cases where either P or H is
positive. Case 6 has Pi and is still surviving after a lapse of 39 months, and case
13 has H 3 of Dukes C but is now positive to the tuberculin test and surviving
at 21 months after the operation. Case 9 is in Stage IV of N3S2HOP3, and only
the main lesion is extirpated. This patient received immunization 4 times and
also a daily administration of PS-K (6g/day). MIF was weakly positive, both
the T-cell count and PHA-blastformation rate improved for about 6 postopera-
tive months, but the MIF disappeared, and T cell count as well as blastformation
rate showed a decreasing tendency in the tenth month, so that BCG alone was
injected. MIF again increased, and ileus occurred at 1.3 postoperative years.
Laparotomy was performed but the P3 observed at the first operation had practi-
cally disappeared. In reviewing the survival of 6 cases of Stage IV gastric cancer
patients immunized with a mixture of BCG and tumor cells, 8 cases of PS-K group
receiving over 720g of PS-K (6g/day) and i.v. injection of 4mg mitomycin C
twice weekly and 17 cases undergoing operation in the same period, the 6-month
survival ratios were 6/6, 7/8, and 15/17 cases, respectively, and the 12-month
survival ratios were 2/6, 3/8 and 8/17 cases, respectively. Stage III patients
receiving BCG plus tumor immunization all survived for 12 months. On check-
ing changes in the tuberculin test before, and 4 weeks after operation, those who
turned positive after operation were: BCG group 3/9 cases, PS-K group 4/13,
and the operation-alone group was 2/26. The group immunized with BCG
showed the highest positive rate. MIF was reinforced in the BCG plus tumor-
immunization group where MIF activity tended to persist for a long period of
time (Fig. 5). The MIF turned negative in 8 of 11 cases prior to clinical con-
firmation of reccurrence. From the above findings, it seems necessary to conduct
immunotherapy more intensively over a longer period of time.
Since 1975 we have been using BCG-CWS that has a stronger immuno-
potentiating power, a uniform chemical property and no danger of infection.
We generally administer mitomycin C, 5-FU and futraful periodically after the
operation, PS-K or ATSO as an immunopotentiator daily, and'BCG-CWS alone
once a week for 4 consecutive weeks and after 6 months once monthly for two
years. The injection of BCG-CWS is continued for two years. In addition, on
the basis of our experimental data that BeG injection into the tumor one week
prior to tumor extirpation prolongs the survival of mice, 100-400 mcg BCG-eWS
in divided doses were injected into the tumor tissues under endoscopy 7-10
days before the operation of gastric cancer and rectal cancer. Ever since Morton's
report (37) of viable BeG injection into melanoma resulting in shrinkage of the
tumor, many reports have appeared. According to statistics by Zbar et at. (38),
melanoma shrinkage was seen in 58% (72/125) (If cases receiving BeG intra-
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Fig. 5. MI activity after operation for stomach cancer. The MIF activity of the BCG
immunotherapy group tended to continue positive longer than that of the control group
without immunotherapy for at least several months after the operation.
tumor injection and in 14% (15/110) of cases n,jt receiving BGG. Similar effects
were observed in cases of mammary cancer and metastatic foci to skin. It is said
that such treatment is effective cnly in cases positive to the tuberculin test and
that there is marked infiltration of histiocytes and small round cells. We also ob-
served redness and edema macroscopically and marked round cell infiltration, the
appearance of Langhans giant cells and cytolysis of cancer cells microscopically at
the BGG-GWS injection site of extirpated tumor specimens of our tuber,culin-
positive cases. Similarly marked swelling and enlargement was observed in
regional lymph nodes.
At early stages of cancer, splenectomy seems to produce anticancer activity
in the tumor-bearing host. When splenectomy is performed 5 days after s.c.
transplantatation of 5.:< 10 6 Ehrlich cancer cells to the back of mouse, the prolif-
erating tumor began to shrink about 20 days later, and 85 % of established tumors
had completely regressed 35 to 50 days later, while control mice with no splenec-
tomy died of tumor effects within 30-50 days. However, splenectomy tended to
result in earlier death if it was performed on day 10 after transplantation. The
survival rate of 89 gastric cancer cases on whom splenectomy was combined with
tumor removal at our surgical department and related hospitals during the period
1965-1969 and in 400 non-splenectomized cases in the same period showed that
15
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the 5-year survival rate was 20.2 % in the splenectomized group and 48.6 % in the
non-splenectomized group. By stages, the survival rate was 100% (2 cases) in
Stage I and 88.9 % (9/11 cases) in Stage II of the splenectomized group, while it
was 87.1 % and 77.1 % in the non-splenectomized group, but in cases of Stages III
and IV the prognosis was poorer in the splenectomized group. There are many
problems yet to be solved before splenectomy is routinely combined with im-
munotherapy, but heightening of host anticancer activity appears possible in the
future by such combined therapeutic procedures.
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